Cytocybernetics
Cytocybernetics is a Buffalo-based biotechnology company founded in 2013 that develops cellular electrophysiology tools and instrumentation for pharmaceutical and academic research laboratories focused on ion-channel and cardiac safety testing.
- Company typePrivate
- Founded2013
- HeadquartersBuffalo, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Cytocybernetics does
Cytocybernetics is a privately held biotechnology company specializing in cellular electrophysiology, founded in 2013 and headquartered in Buffalo, New York. The company operates with a small team of 1–10 employees and is led by founder and CEO Glenna Bett, with Gary Rasmusson serving as Chief Scientific Officer and Randall Rasmusson as President. Its focus on cellular electrophysiology places it in the life-science tools and instrumentation segment that supplies drug-discovery and safety-pharmacology researchers with platforms for measuring the electrical activity of cells, a capability critical to cardiac safety assessment (e.g., CiPA-style testing), ion-channel drug screening, and basic cardiac and neuroscience research.
The company has sustained operations primarily through non-dilutive and early-stage institutional capital, accumulating approximately $3.77M across four disclosed funding events. These include a 2015 Seed/Series 1 round from the 43North Buffalo startup competition ($1.0M), a 2018 round from the University at Buffalo ($1.5M), a 2019 NSF SBIR/STTR award ($269,900), and a 2022 NSF award ($1.0M). The pattern indicates a capital strategy reliant on government grants and university/regional institutional backing rather than venture-scale equity financings.
Public commercial information is thin: no customer logos, pricing model, distribution channels, or named product lines are disclosed in the input data, and the corporate website (cytocybernetics.com) was reported as a loading/verification page at time of capture. The business model is therefore best characterized as an early-stage research-tools vendor likely monetizing instruments, consumables, assays, or software licenses to academic and pharmaceutical research laboratories, though no revenue figures, customer counts, or contract terms have been disclosed.
Cytocybernetics firmographics
Firmographics- Name
- Cytocybernetics
- Website
- https://cytocybernetics.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Cytocybernetics is a Buffalo-based biotechnology company founded in 2013 that develops cellular electrophysiology tools and instrumentation for pharmaceutical and academic research laboratories focused on ion-channel and cardiac safety testing.
- Ownership category
- akta.pro rank
Cytocybernetics industry classification
Industry- Product category
- Cellular Electrophysiology Instruments
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Services-Commercial Physical & Biological Research (8731), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Cell-Based & Potency Assays (Bioassays) (HLAGADAH)
- akta.pro secondary industries
- Flow Cytometry & Cellular Analysis Diagnostics (HLAHAAAF), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)
Keywords
Where Cytocybernetics is headquartered
LocationHeadquarters
- HQ city
- Buffalo
- HQ country
- United States
- HQ region
- North America
Markets served
Cytocybernetics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Cytocybernetics product offering
Product offeringCore offering
Cytocybernetics specializes in cellular electrophysiology, developing and providing instruments and tools that enable researchers to measure and analyze the electrical properties of biological cells. Its offerings are aimed at academic research laboratories and pharmaceutical/biotech drug discovery teams that require high-fidelity electrophysiological data.
Differentiator
Problem solved
Functional benefit
Companies that use Cytocybernetics
Customer profileIdeal customer profiles1 record
Cytocybernetics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Cytocybernetics partnerships and signals
Strategic signalRecent moves2 records
Expansion highlights2 records
Cytocybernetics competitors and assessment
Company assessmentBroad incumbents
- Molecular Devices (Danaher): The dominant automated patch clamp (APC) and electrophysiology instrument vendor (PatchXpress, IonWorks, Axopatch), now part of Danaher's Life Sciences segment. Directly comparable because it sells the same class of cellular electrophysiology instruments and serves the same ion-channel drug discovery and cardiac safety customer base.
- Charles River Laboratories: Large CRO offering cardiac safety and electrophysiology screening services (including manual patch clamp and CiPA-aligned assays). Comparable as a buyer and adjacent provider of cellular electrophysiology services to pharma, even though it is not an instrument OEM.
- Multi Channel Systems (MaxWell Biosystems): Manufacturer of microelectrode array (MEA) and electrophysiology recording platforms. Comparable to Cytocybernetics as a developer of cellular electrophysiology measurement instruments used in academic and pharma research.
Direct peers
- Nanion Technologies: German specialist in automated patch clamp and electrophysiology instrumentation (Port-a-Patch, SyncroPatch, Vesicle Prep Pro). Closely comparable as a focused APC vendor serving ion-channel research and safety pharmacology customers.
- Sophion Bioscience: Specialized APC platform vendor (QPatch) for ion-channel drug discovery and safety screening. Closely comparable to Cytocybernetics as a dedicated electrophysiology instrument company serving pharma/biotech electrophysiology customers.
- Metrion Biosciences: UK-based contract research organization specializing in ion channel and cardiac safety electrophysiology assays. Comparable because it operates at the intersection of electrophysiology services and instrument-dependent workflows targeting the same pharma customers.
- B'SYS: Swiss ion-channel and electrophysiology CRO offering screening and safety assay services using APC platforms. Comparable to Cytocybernetics because it serves the same pharma ion-channel screening and cardiac safety use cases.
- Axxam: Italian electrophysiology-focused CRO providing ion-channel and cell-based assay services for drug discovery. Comparable as an electrophysiology specialist serving the same pharma/biotech screening customers.
Emerging players
- Nanion subsidiary (Nalion/HESI/CiPA-aligned APC vendors): Smaller APC and CiPA-aligned safety pharmacology vendors serving cardiac safety electrophysiology customers. Comparable as emerging specialists competing against incumbents in the same electrophysiology workflow that Cytocybernetics targets.
Regional players
- Nanion (Nanion Inc., US subsidiary): US commercial arm of Nanion Technologies focused on automated patch clamp. Comparable as the same APC product category with regional sales overlap to Cytocybernetics' US-based customer base.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Cytocybernetics social profiles
Digital presenceCytocybernetics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cytocybernetics leadership team
Management profileNumber of profiles
Profiles3 records
Cytocybernetics funding detail
Funding detailFunding overview
Funding rounds4 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cytocybernetics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cytocybernetics
What does Cytocybernetics do?
Cytocybernetics specializes in cellular electrophysiology, developing and providing instruments and tools that enable researchers to measure and analyze the electrical properties of biological cells. Its offerings are aimed at academic research laboratories and pharmaceutical/biotech drug discovery teams that require high-fidelity electrophysiological data.
Is Cytocybernetics a public or private company?
Cytocybernetics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Cytocybernetics founded?
Cytocybernetics was founded in 2013. It employs 1 to 10 people.
Where is Cytocybernetics based?
Cytocybernetics is headquartered in Buffalo, United States, in the North America region.
Who are Cytocybernetics's main competitors?
Broad incumbents on record are Molecular Devices (Danaher), Charles River Laboratories and Multi Channel Systems (MaxWell Biosystems). Direct peers are Nanion Technologies, Sophion Bioscience, Metrion Biosciences, B'SYS and Axxam. Nanion subsidiary (Nalion/HESI/CiPA-aligned APC vendors) is listed as an emerging player. Nanion (Nanion Inc., US subsidiary) is listed as a regional player.
Does Cytocybernetics have an API?
No public API is recorded for Cytocybernetics.
What industry is Cytocybernetics in?
Cytocybernetics's product category is Cellular Electrophysiology Instruments. Its primary akta.pro industry code is HLAGADAH, Cell-Based & Potency Assays (Bioassays), with a secondary code of HLAHAAAF, Flow Cytometry & Cellular Analysis Diagnostics. Its NAICS code is 334510 and its SIC code is 8731.